Bloor K, Leese B, Maynard A
Centre for Health Economics, University of York, Heslington, U.K.
Eur J Cancer. 1994;30A(4):463-8. doi: 10.1016/0959-8049(94)90420-0.
The economic evaluation of any new or existing therapy should include a comprehensive appraisal of costs. When evaluating pharmaceutical interventions, it is inappropriate to identify the purchase price alone. Other relevant costs include the costs of time of doctors, nurses and other personnel in administering and monitoring the effects of the therapy, and the costs of treating any side-effects. This study estimates direct National Health Service (NHS) costs in the U.K. of current medical practice in managing severe cancer pain, using a review of the published literature and constructing a cost analysis for four 'typical' patients. Costs are estimated for patients with severe cancer pain in a hospital and an ambulatory setting, with oral and subcutaneous routes of drug administration. The study includes costs of drugs, supplies, equipment and personnel time. The results demonstrate the importance of personnel time costs, and potential cost savings which could result from the use of transdermally administered opioid analgesics.
对任何新的或现有的治疗方法进行经济评估时，都应全面评估成本。在评估药物干预措施时，仅确定购买价格是不合适的。其他相关成本包括医生、护士和其他人员在实施和监测治疗效果时所花费的时间成本，以及治疗任何副作用的成本。本研究通过回顾已发表的文献并为四名“典型”患者构建成本分析，估算了英国国家医疗服务体系（NHS）当前管理重度癌症疼痛的医疗实践中的直接成本。估算了在医院和门诊环境中，采用口服和皮下给药途径的重度癌症疼痛患者的成本。该研究包括药物、用品、设备和人员时间成本。结果表明了人员时间成本的重要性，以及使用经皮给药的阿片类镇痛药可能带来的潜在成本节约。
